Coagulation And Hyperlipidemia Drugs Flashcards
Vitamin K antagonist - anticoagulant/anti-platelet, example and MOA
Anticoagulant
Ex. Warfarin (Coumadin)
Inhibits vitamin K dependent clotting factors
Vitamin K antagonist - clinical utility, SE
Clinical: a-fib, DVT/PE prevention and tx, valve replacement
SE: bleeding, skin necrosis (rare), teratogenic
Direct thrombin inhibitors - anticoagulant/anti-platelet, example, MOA
Anticoagulant
Dabigatran (Pradaxa)
MOA: inhibits thrombin directly
Dabigatran - clinical utility, SE
Clinical: a-fib, DVT/PE tx
SE: bleeding, GI symptoms
Apixaban MOA
inhibit factor Xa, preventing prothrombin conversion to thrombin
Apixaban SE
SE: bleeding, elevated liver enzymes
Heparin MOA
Enhance activity of antithrombin, inhibiting thrombin and Factor Xa
Heparin SE
Bleeding, heparin-induced thrombocytopenia (HIT)
Aspirin MOA
Irreversibly inhibit COX-1, reducing thromboxane A2 production leading to decreased platelet aggregation
Aspirin SE
bleeding, gastric ulceration, tinnitus
Clopidogrel MOA
Inhibits platelet P2Y12 ADP receptor reducing platelet activation and aggregation
Clopidogrel SE
bleeding, dyspnea (ticagrelor)
Alteplase MOA
Activate plasminogen to plasmin, which digests fibrin and dissolves clots
Alteplase SE
bleeding (including intracranial hemorrhage), allergic reactions (streptokinase)
4 main indications for anticoagulation therapy
Main adverse effect
Indications: DVT, PE, atrial fibrillation, MI
AE: bleeding
Statins SE
myalgia, increased liver enzymes, rhabdomyolysis (rare)
Statins (HMG-CoA reductase inhibitors) MOA
inhibit HMG-CoA reductase enzyme which plays a role in cholesterol production
Bile acid sequestrants - examples, MOA
Cholestyramine, colestipol, colesevelam
Bind bile acids in the intestines, promoting their excretion and reducing circulating cholesterol
Bile acid sequestrants - clinical indications, SE
Hypercholesterolemia
SE: constipation, bloating, indigestion
Ezetimibe MOA
Inhibits cholesterol, absorption in small intestine
Ezetimibe SE
diarrhea, joint pain, sinusitis, fatigue
PCSK9 inhibitors - examples, MOA (not on study guide)
Evolocumab, alirocumab
MOA: monoclonal antibodies that inhibit PCSK9, increasing LDL receptor availability and reducing LDL cholesterol
PCSK9 inhibitors - clinical indications, SE (not on study guide)
HeFH, ASCVD requiring additional LDL-C lowering
SE: nasopharyngitis, injection site reactions
Fenofibrate MOA
activate PPAR alpha, reducing triglyceride synthesis and enhancing triglyceride clearance